Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary CNS lymphoma chemotherapy induction with rituximab/thiotepa variations followed by WBRT or autologous stem cell transplant consolidation
ISRCTN49014661Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of methotrexate, cytarabine, rituximab, thiotepa and carmustine in primary central nervous system lymphoma (PCNSL) and non-Hodgkin lymphoma (NHL) (5 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Complete remission following primary chemotherapy. Started Oct 2011; status: completed.
02
Drugs
methotrexatecytarabinerituximabthiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ISRCTN49014661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49014661.